This inventor holds 1 USPTO granted patent. Top assignee: The Medicines Company (Leipzig) Gmbh. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: The Innovations of Daniel Doennecke
Introduction
Daniel Doennecke is a notable inventor based in Weimar, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target coagulation factors. His work is essential for advancing treatments for cardiovascular and thrombotic events.
Latest Patents
Daniel Doennecke holds a patent for 2-(aminomethyl)-5-chlorobenzylamide derivatives and their use as inhibitors of the clotting factor Xa. This innovation is crucial as it provides new options for the treatment and prophylaxis of cardiovascular and thrombotic events. The patent highlights the potential of these compounds in improving patient outcomes in critical medical situations.
Career Highlights
Doennecke is associated with The Medicines Company (Leipzig) GmbH, where he has been instrumental in research and development. His expertise in pharmacology and chemistry has led to advancements in therapeutic solutions that address significant health challenges.
Collaborations
Throughout his career, Daniel has collaborated with esteemed colleagues such as Andrea Schweinitz and Joerg Stuerzebecher. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new medical therapies.
Conclusion
Daniel Doennecke's contributions to the field of pharmaceuticals through his innovative patents and collaborations underscore his importance as an inventor. His work continues to pave the way for advancements in medical treatments that can significantly impact patient care.